Our focus is on neurochemicals acting on the peripheral and central nervous system

We are enthusiastic about neurochemicals acting as agonists or antagonists on G-protein coupled receptors located in the peripheral and central nervous system. Our goal is to address the clinical needs to diagnose and treat the neurological pathologies at the origin of the disease; thus, avoiding a merely systematic treatment and rather stopping or delaying disease progression.

The chemical structure of small molecules is the key for successful drug design and development for both imaging probes and therapeutics. The combined, interdisciplinary knowledge of medicinal chemists, pharmacists and physicians allows drug adjustment and pave the way towards the application of our substances as tools for image-guided therapy.

The bottleneck of the drug development process is the preclinical screening of a compound library, as we still lack substantial methods for a fast and reliable biological assessment. We developed a complex dynamic 3D-cell culture method, which mimics the tissue situation and has the potential to fasten the screening process. Moreover, it conforms with the 3Rs (reduce, replace, refine) rule in animal ethics and will contribute to reduce the number of animals needed in drug testing.

Our main interests lie in

  • Inventive drug and tracer development of neurochemicals
  • Innovative drug screening methods
  • Interdisciplinary approaches close to medical application

We are currently open for masterstudents

To start a master thesis in our group, all major examinations must be completed (M1, M2, M3, M4, M5, M6, M8, M11). In total, a maximum of 15 ECTS may still be open, excluding the ECTS associated with the master thesis. Ideally, all examinations should be completed.

EANM 2021 Plenary Lecture - Isotopes Past and Future

Missed the EANM 2021 plenary lecture on the availability of medicinal radioisotopes.

You can still watch it here.

CBmeds microONE promo video

For the SDG-3 presentation at the austrian parlament, our consortium of the FFG funded microONE project (CBmed, Univie, MUW, among others) produced a nice promo-video. Thank you to Thomas Wadsak for the nice production. (German only)

News and announcements

05.12.2024
 

We are surrounded by plastic that gradually breaks down into tiny particles, finding its way into our bodies. In this lecture, we will explore the pathways of microplastics and their impact on our health.

05.12.2024
 

A set of tires loses an average of over four kilograms in weight. In Europe alone, this amounts to 500,000 tons of microplastics per year that end up in the environment – and even in your side salad. What few people know: Tire abrasion is the largest source of microplastics.Some of the microplastics we ingest remain in our bodies and can pose serious health risks.

25.11.2024
 

We recently attended ApoKongress, focusing on liver diseases. The event provided an excellent platform for insightful discussions and knowledge exchange with experts in the field.

25.11.2024
 

Sarah Stellnberger has received the Poster Prize at DocSchool for her work in the field of Life Sciences. This acknowledgment highlights the quality and impact of her research. Congratulations to Sarah on this accomplishment.

12.11.2024
 

The 1st Symposium of the Joint Applied Medicinal Radiochemistry Facility took place at the UniVie today. The goal was to bring together Viennese scientists in the field of radiopharmaceutical/chemical sciences to increase the awareness of available expertise and equipment in order to foster future collaborations. Our PI, Verena, was invited to present our ongoing projects.

12.11.2024
 

This year’s VBC PhD Symposium theme, ‘Into the Unknown’, aims to highlight the exploratory science that interrogates the unknown and allows us to understand the mechanisms that govern life. Our PhD students, Verena and Irem, proudly presented their ongoing research.